TABLE 1.
Baseline sociodemographic and clinical characteristics of the study participants (N = 780).
| Sex | |
| Female n (%) | 495 (63.5) |
| Male n (%) | 285 (36.5) |
| Age | |
| Median (1st–3rd quartile) | 65.0 (56.0–63.9) |
| Primary tumor | |
| Breast n (%) | 422 (54.1) |
| Genito‐urinary n (%) | 40 (5.1) |
| Lung n (%) | 76 (9.8) |
| Melanoma n (%) | 18 (2.3) |
| Prostate n (%) | 143 (18.3) |
| Other n (%) | 81 (10.4) |
| Diabetes | |
| Yes n (%) | 55 (7.1) |
| No n (%) | 725 (92.9) |
| Previous antiangiogenic (AA) therapy(*) | |
| Yes n (%) | 35 (4.5) |
| No n (%) | 745 (95.5) |
| Preventive dental treatments | |
| Yes n (%) | 71 (9.1) |
| No n (%) | 709 (90.9) |
| Previous bisphosphonate | |
| Yes n (%) | 148 (19.0) |
| No n (%) | 632 (81.0) |
| Previous MRONJ | |
| Yes n (%) | 4 (0.05) |
| No n (%) | 776 (99.5) |
Note: (*) started before Dmab.